APCR
0.004
300%
IMC
0.039
-40%
MEU
0.12
71.4%
JNS
0.058
-38.9%
IFG
0.017
70%
TMB
0.049
-34.7%
VRC
0.01
66.7%
MIO
0.02
-33.3%
ALV
0.085
63.5%
PET
0.014
-30%
CTN
0.003
50%
CRS
0.091
-27.2%
IMM
0.375
47.1%
DTM
0.035
-27.1%
PER
0.01
42.9%
BAP
1.76
-25.1%
AUA
0.04
37.9%
NES
0.006
-25%
STV
0.011
37.5%
A11
0.155
-24.4%
ELS
2.67
35.5%
WNX
0.125
-24.2%
AGY
0.095
33.8%
AM5
0.007
-22.2%
ALY
0.012
33.3%
KLV
0.007
-22.2%
CHM
0.004
33.3%
NFL
0.11
-21.4%
RHY
0.105
32.9%
MNB
0.023
-20.7%
AR9
0.13
32.7%
CKA
0.054
-20.6%
ASL
2.43
31.4%
HVY
0.5
-20%
X2M
0.013
30%
TYX
0.004
-20%
LRM
0.031
29.2%
LKY
0.205
-19.6%
SPD
1.565
28.8%
SUM
0.033
-19.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Chimeric Therapeutics (ASX:CHM): Reports first patient enrolled in chm clinical trial

Chimeric Therapeutics (ASX:CHM) has reported that the first participant has been enrolled in the Phase 1/2 multi-center clinical trial for CHM CDH17 cell therapy.

🩺 This therapy targets advanced gastrointestinal cancers like colorectal cancer, gastric cancer, and neuroendocrine tumors.
🏆 The trial aims to find the recommended dose and assess safety and effectiveness.

ASX announcement: https://announcements.asx.com.au/asxpdf/20240722/pdf/065szt55mn24fq.pdf